Reviewer's report
Title:Abdominal Attacks and Treatment in Hereditary Angioedema with
C1-Inhibitor Deficiency
Version:2Date:9 March 2014
Reviewer: Timothy Craig
Reviewer's report:
I had the opportunity to review your manuscript titled
“Abdominal Attacks and Treatment in Hereditary Angioedema with C1-
Inhibitor Deficiency
By Eitan Rubinstein MD1, Leslie E. Stolz PhD2, Albert L. Sheffer MD3, Chris
Stevens MD2, Athos Bousvaros MD”
Thank you very much for the opportunity. Your manuscript was well written and
well thought out; however, I have a few suggestions that may help in improving
the manuscript.
Abstract- no needed changes
Introduction-
Please remove the following
“(EDEMA0,
EDEMA1®, EDEMA2®, EDEMA3®-Double Blind, EDEMA3®-Repeat Dosing,
EDEMA4®,
DX-88/19) and report the results of ecallantide (KALBITOR®, Dyax Corp.,
Burlington, MA)
treatment.”
In the last sentence, next to Gastroenterologist, please add “Surgeon and ED
Physician”.
Methods:
Well done
Results:
Should be DATA WERE
“data from EDEMA0, EDEMA1, EDEMA2 and DX-88/19 was analyzed”
Do you have data on CT scans of the abdomen? If so please include these data.
Discussions:
Although the statement ”Once the diagnosis is suspected, blood tests can
confirm the diagnosis” is true please specify that rarely are the results available
at the time of a patient presenting unless they are already diagnosed. Please add
that these will be important data to obtain in the ED for future attacks since the
treatment of HAE is unique.
Please reference the 4 “Guidelines” so that the GI community is aware of these
publications. This should include Canadian-HUNG, WAO, HAWK and the HAE_A
Please include Dr Bieddenkapp as an author. None of the authors were involved
in the EDEMA program and I am sure did not analyze these data. For this reason
please remove the line “The authors wish to thank Joseph Biedenkapp, PhD
(Dyax Corp.) for his assistance with the drafting of this manuscript.” And add him
as an author unless you are able to show he had less to do with this manuscript
than the present authors did.
Thank you for the opportunity. I enjoyed the manuscript and it is well done.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
no concerns
Reviewer's report
Title:Abdominal Attacks and Treatment in Hereditary Angioedema with
C1-Inhibitor Deficiency
Version:2Date:9 March 2014
Reviewer: Timothy Craig
Reviewer's report:
I had the opportunity to review your manuscript titled
“Abdominal Attacks and Treatment in Hereditary Angioedema with C1-
Inhibitor Deficiency
By Eitan Rubinstein MD1, Leslie E. Stolz PhD2, Albert L. Sheffer MD3, Chris
Stevens MD2, Athos Bousvaros MD”
Thank you very much for the opportunity. Your manuscript was well written and
well thought out; however, I have a few suggestions that may help in improving
the manuscript.
Abstract- no needed changes
Introduction-
Please remove the following
“(EDEMA0,
EDEMA1®, EDEMA2®, EDEMA3®-Double Blind, EDEMA3®-Repeat Dosing,
EDEMA4®,
DX-88/19) and report the results of ecallantide (KALBITOR®, Dyax Corp.,
Burlington, MA)
treatment.”
In the last sentence, next to Gastroenterologist, please add “Surgeon and ED
Physician”.
Methods:
Well done
Results:
Should be DATA WERE
“data from EDEMA0, EDEMA1, EDEMA2 and DX-88/19 was analyzed”
Do you have data on CT scans of the abdomen? If so please include these data.
Discussions:
Although the statement ”Once the diagnosis is suspected, blood tests can
confirm the diagnosis” is true please specify that rarely are the results available
at the time of a patient presenting unless they are already diagnosed. Please add
that these will be important data to obtain in the ED for future attacks since the
treatment of HAE is unique.
Please reference the 4 “Guidelines” so that the GI community is aware of these
publications. This should include Canadian-HUNG, WAO, HAWK and the HAE_A
Please include Dr Bieddenkapp as an author. None of the authors were involved
in the EDEMA program and I am sure did not analyze these data. For this reason
please remove the line “The authors wish to thank Joseph Biedenkapp, PhD
(Dyax Corp.) for his assistance with the drafting of this manuscript.” And add him
as an author unless you are able to show he had less to do with this manuscript
than the present authors did.
Thank you for the opportunity. I enjoyed the manuscript and it is well done.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
no concerns
Please review this paper.
user
Reviewer's report
Title:Abdominal Attacks and Treatment in Hereditary Angioedema with
C1-Inhibitor Deficiency
Version:2Date:9 March 2014
Reviewer: Timothy Craig
Reviewer's report:
I had the opportunity to review your manuscript titled
“Abdominal Attacks and Treatment in Hereditary Angioedema with C1-
Inhibitor Deficiency
By Eitan Rubinstein MD1, Leslie E. Stolz PhD2, Albert L. Sheffer MD3, Chris
Stevens MD2, Athos Bousvaros MD”
Thank you very much for the opportunity. Your manuscript was well written and
well thought out; however, I have a few suggestions that may help in improving
the manuscript.
Abstract- no needed changes
Introduction-
Please remove the following
“(EDEMA0,
EDEMA1®, EDEMA2®, EDEMA3®-Double Blind, EDEMA3®-Repeat Dosing,
EDEMA4®,
DX-88/19) and report the results of ecallantide (KALBITOR®, Dyax Corp.,
Burlington, MA)
treatment.”
In the last sentence, next to Gastroenterologist, please add “Surgeon and ED
Physician”.
Methods:
Well done
Results:
Should be DATA WERE
“data from EDEMA0, EDEMA1, EDEMA2 and DX-88/19 was analyzed”
Do you have data on CT scans of the abdomen? If so please include these data.
Discussions:
Although the statement ”Once the diagnosis is suspected, blood tests can
confirm the diagnosis” is true please specify that rarely are the results available
at the time of a patient presenting unless they are already diagnosed. Please add
that these will be important data to obtain in the ED for future attacks since the
treatment of HAE is unique.
Please reference the 4 “Guidelines” so that the GI community is aware of these
publications. This should include Canadian-HUNG, WAO, HAWK and the HAE_A
Please include Dr Bieddenkapp as an author. None of the authors were involved
in the EDEMA program and I am sure did not analyze these data. For this reason
please remove the line “The authors wish to thank Joseph Biedenkapp, PhD
(Dyax Corp.) for his assistance with the drafting of this manuscript.” And add him
as an author unless you are able to show he had less to do with this manuscript
than the present authors did.
Thank you for the opportunity. I enjoyed the manuscript and it is well done.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
no concerns
assistant